Advanced Biomed Inc. (NASDAQ:ADVB) Sees Significant Growth in Short Interest

Posted by Geri Gentry on Aug 14th, 2026

Advanced Biomed Inc. (NASDAQ:ADVB – Get Free Report) saw a large increase in short interest in the month of July. As of July 31st, there was short interest totaling 57,213 shares, an increase of 441.2% from the July 15th total of 10,571 shares. Approximately 4.7% of the company’s shares are short sold. Based on an average daily volume of 8,635,838 shares, the days-to-cover ratio is currently 0.0 days.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Advanced Biomed from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 23rd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

View Our Latest Research Report on ADVB

Institutional Investors Weigh In On Advanced Biomed

An institutional investor recently bought a new position in Advanced Biomed stock. BlackRock Inc. bought a new stake in Advanced Biomed Inc. (NASDAQ:ADVB – Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 59,944 shares of the company’s stock, valued at approximately $186,000. BlackRock Inc. owned about 3.63% of Advanced Biomed as of its most recent filing with the Securities and Exchange Commission.

Advanced Biomed Stock Up 12.9%

Shares of NASDAQ:ADVB opened at $8.58 on Friday. The firm has a market cap of $14.16 million, a price-to-earnings ratio of 1.78 and a beta of -0.39. The company’s fifty day simple moving average is $6.72 and its 200 day simple moving average is $5.56. Advanced Biomed has a 12 month low of $3.61 and a 12 month high of $24.23.

Advanced Biomed (NASDAQ:ADVB – Get Free Report) last posted its quarterly earnings data on Saturday, May 16th. The company reported ($0.38) earnings per share for the quarter.

About Advanced Biomed

(Get Free Report)

Our Mission We are committed to the application research of integrating semiconductor technology and biotechnology. Through the enrichment, capture, and identification of circulating tumor cells and related tumor marker cells in the field of liquid biopsy, we aim to provide cancer patients with rapid and affordable assay products and services. These services include early screening and detection, diagnosis and staging, treatment selection, and patient outcome interventions for cancer. We are a holding company incorporated in the State of Nevada.